Defining the molecular basis of Arf and Hdm2 interactions

被引:101
作者
Bothner, B
Lewis, WS
DiGiammarino, EL
Weber, JD
Bothner, SJ
Kriwacki, RW
机构
[1] St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA
[3] St Jude Childrens Res Hosp, Hartwell Ctr Biotechnol & Bioinformat, Memphis, TN 38105 USA
[4] St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA
[5] Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA
关键词
p53; nucleolar localization; supramolecular assemblies; dynamic disorder; ubiquitination;
D O I
10.1006/jmbi.2001.5110
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Understanding the interaction of Arf and Hdm2 has recently become a central issue in cancer biology. In response to hyperproliferative signals, p14(Arf) stabilizes p53 by binding to Hdm2 and inhibits the ubiquitination and subsequent proteosome-dependent degradation of p53. The medical importance of the Arf-Hdm2-p53 regulatory system is highlighted by the finding that either p53 or p14(Arf) are lost or modified in virtually all human cancers. Isolated Arf and Hdm2 domains are dynamically disordered in solution, yet they retain the ability to interact in vitro and in cellular assays. Upon binding, domains of both Arf and Hdm2 undergo ad structures dramatic transition from disordered conformations to extended comprised of beta -strands. The presence of domains from both proteins are necessary and sufficient for the formation of the highly stable extended beta structures. We have mapped sites within Arf and Hdm2 that interact at a resolution of five amino acid residues using surface plasmon resonance. Surface plasmon resonance and circular dichroism spectropolarimetry confirm the presence of multiple interaction domains within each protein. Both p14(Arf) (human) and p19(Arf) (mouse) interact with Hdm2 through two short motifs present in their N termini. The Arf interacting region of Hdm2 is also composed of two short sequences located in the central acidic domain, between residues 235-264 and 270-289. The binding-induced structural transition is also induced by short peptides, 15 amino acids in length, that contain the binding motifs. Micro-injection and live cell imaging of proteins tagged with fluorescent labels was used to confirm the in vivo function of the interaction domains. Arf and Hdm2 thus appear to interact through a novel mechanism that exerts control over the cell division cycle. The novel molecular mechanism of interaction and the limited size of the protein domains involved provide opportunities for the development of anticancer therapeutics. (C) 2001 Academic Press.
引用
收藏
页码:263 / 277
页数:15
相关论文
共 64 条
  • [1] The contribution of the RING finger domain of MDM2 to cell cycle progression
    Argentini, M
    Barboule, N
    Wasylyk, B
    [J]. ONCOGENE, 2000, 19 (34) : 3849 - 3857
  • [2] MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY
    BARAK, Y
    JUVEN, T
    HAFFNER, R
    OREN, M
    [J]. EMBO JOURNAL, 1993, 12 (02) : 461 - 468
  • [3] p14ARF links the tumour suppressors RB and p53
    Bates, S
    Phillips, AC
    Clark, PA
    Stott, F
    Peters, G
    Ludwig, RL
    Vousden, KH
    [J]. NATURE, 1998, 395 (6698) : 124 - 125
  • [4] THE P53-ASSOCIATED PROTEIN MDM2 CONTAINS A NEWLY CHARACTERIZED ZINC-BINDING DOMAIN CALLED THE RING FINGER
    BODDY, MN
    FREEMONT, PS
    BORDEN, KLB
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 1994, 19 (05) : 198 - 199
  • [5] NATURAL ABUNDANCE N-15 NMR BY ENHANCED HETERONUCLEAR SPECTROSCOPY
    BODENHAUSEN, G
    RUBEN, DJ
    [J]. CHEMICAL PHYSICS LETTERS, 1980, 69 (01) : 185 - 189
  • [6] An intact HDM2 RING-finger domain is required for nuclear exclusion of p53
    Boyd, SD
    Tsai, KY
    Jacks, T
    [J]. NATURE CELL BIOLOGY, 2000, 2 (09) : 563 - 568
  • [7] Creighton TE, 1993, PROTEINS STRUCTURES
  • [8] Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO
  • [9] 2-Q
  • [10] E1A signaling to p53 involves the p19ARF tumor suppressor
    de Stanchina, E
    McCurrach, ME
    Zindy, F
    Shieh, SY
    Ferbeyre, G
    Samuelson, AV
    Prives, C
    Roussel, MF
    Sherr, CJ
    Lowe, SW
    [J]. GENES & DEVELOPMENT, 1998, 12 (15) : 2434 - 2442